DR. MARVIN ROBERT GAROVOY, M.D.
Medical Practice at Dutch Valley Ln, San Anselmo, CA
License number
California G28644
Category
Medical Practice
Type
Specialist
Address
Address
9 Dutch Valley Ln, San Anselmo, CA 94960
Phone
(415) 454-9052
(415) 453-6152 (Fax)
(415) 453-6152 (Fax)
Professional information
Dr. Marvin R Garovoy, San Anselmo CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
9 Dutch Valley Ln, San Anselmo 94960
(415) 454-9052 (Phone), (415) 453-6152 (Fax)
(415) 454-9052 (Phone), (415) 453-6152 (Fax)
Certifications:
Internal Medicine, 1974
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Suny Downstate Medical Center
Graduated: 1969
Bellevue Hospital Center
Peter Bent Brigham Hosp
Suny Downstate Medical Center
Graduated: 1969
Bellevue Hospital Center
Peter Bent Brigham Hosp
Polynucleotide Decoys That Inhibit Mhc-Ii Expression And Uses Thereof
US Patent:
6410721, Jun 25, 2002
Filed:
Jan 5, 1999
Appl. No.:
09/225645
Inventors:
C. Anthony Hunt - San Francisco CA
Carol Lim - San Francisco CA
Marvin R. Garovoy - San Anselmo CA
Carol Lim - San Francisco CA
Marvin R. Garovoy - San Anselmo CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 2104
US Classification:
536 241, 536 231, 536 245, 4353201, 435455, 514 44
Abstract:
The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the hosts immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen. Further, because of the role of RF-X in the expression of several viral proteins, the polynucleotide decoys of the invention can be used in methods of treating an individual infected with hepatitis B virus, or cytomegalovirus.
Treatment Method
US Patent:
6582698, Jun 24, 2003
Filed:
Mar 28, 2001
Appl. No.:
09/819921
Inventors:
Russell L. Dedrick - Kensington CA
Marvin R. Garovoy - San Anselmo CA
Susan M. Kramer - San Francisco CA
Karen M. Starko - Hillsborough CA
Marvin R. Garovoy - San Anselmo CA
Susan M. Kramer - San Francisco CA
Karen M. Starko - Hillsborough CA
Assignee:
Genentech, Inc. - South San Francisco CA
XOMA Technology, Ltd. - Berkeley CA
XOMA Technology, Ltd. - Berkeley CA
International Classification:
A61K 39395
US Classification:
4241331, 4241731, 4241441, 4241541
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Treatment Of Lfa-1 Associated Disorders With Increasing Doses Of Lfa-1 Antagonist
US Patent:
6652855, Nov 25, 2003
Filed:
Feb 11, 2002
Appl. No.:
09/936603
Inventors:
Marvin R. Garovoy - San Anselmo CA
Susan M. Kramer - San Francisco CA
Russell L. Dedrick - Kensington CA
Karen Starko - Hillsborough CA
Susan M. Kramer - San Francisco CA
Russell L. Dedrick - Kensington CA
Karen Starko - Hillsborough CA
Assignee:
Genentech, Inc. - South San Francisco CA
XOMA Ltd. - Berkeley CA
XOMA Ltd. - Berkeley CA
International Classification:
A61K 39395
US Classification:
4241331, 4241341, 4241541, 4241731, 53038822, 5303873
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Polynucleotide Decoys That Inhibit Mhc-Ii Expression And Uses Thereof
US Patent:
5859226, Jan 12, 1999
Filed:
Jul 27, 1994
Appl. No.:
8/281423
Inventors:
C. Anthony Hunt - San Francisco CA
Carol Lim - San Francisco CA
Marvin R. Garovoy - San Anselmo CA
Carol Lim - San Francisco CA
Marvin R. Garovoy - San Anselmo CA
Assignee:
Regents of the University of California, The - Oakland CA
International Classification:
C07H 2104
US Classification:
536 241
Abstract:
The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the host's immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen. Further, because of the role of RF-X in the expression of several viral proteins, the polynucleotide decoys of the invention can be used in methods of treating an individual infected with hepatitis B virus, or cytomegalovirus.
Treatment Of Lfa-1 Associated Disorders With Increasing Doses Of Lfa-1 Antagonist
US Patent:
2008005, Feb 28, 2008
Filed:
Oct 30, 2007
Appl. No.:
11/929604
Inventors:
Marvin Garovoy - San Anselmo CA, US
Susan Kramer - San Francisco CA, US
Russell Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
Susan Kramer - San Francisco CA, US
Russell Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
Xoma Ltd. - Berkeley CA
Xoma Ltd. - Berkeley CA
International Classification:
A61K 31/395, A61P 43/00
US Classification:
424130100, 424133100
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Treatment Of Lfa-1 Associated Disorders With Increasing Doses
US Patent:
2004004, Mar 11, 2004
Filed:
Sep 5, 2003
Appl. No.:
10/655905
Inventors:
Marvin Garovoy - San Anselmo CA, US
Susan Kramer - San Francisco CA, US
Russell Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
Susan Kramer - San Francisco CA, US
Russell Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
International Classification:
A61K039/395
US Classification:
424/143100
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Treatment Of Lfa-1 Associated Disorders With Increasing Doses Of Lfa-1 Antagonist
US Patent:
7364734, Apr 29, 2008
Filed:
Mar 10, 2005
Appl. No.:
11/078332
Inventors:
Marvin R. Garovoy - San Anselmo CA, US
Susan M. Kramer - San Francisco CA, US
Russell L. Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
Susan M. Kramer - San Francisco CA, US
Russell L. Dedrick - Kensington CA, US
Karen Starko - Hillsborough CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
US Classification:
4241441, 4241521, 4241541
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Treatment Method
US Patent:
2003022, Dec 4, 2003
Filed:
Jun 20, 2003
Appl. No.:
10/600633
Inventors:
Russell Dedrick - Kensington CA, US
Marvin Garovoy - San Anselmo CA, US
Susan Kramer - San Francisco CA, US
Karen Starko - Hillsborough CA, US
Marvin Garovoy - San Anselmo CA, US
Susan Kramer - San Francisco CA, US
Karen Starko - Hillsborough CA, US
International Classification:
A61K039/395
US Classification:
424/130100
Abstract:
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.